~~<i id='20F017F853'><strike id='20F017F853'><tt id='20F017F853'><pre id='20F017F853'></pre></tt></strike></i>~~

Home» knowledge» focus

focus

author：leisure time 2025-10-01 15:05:15 Page View：6899

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tuberculosis patients need more than just free medication
Next article： In Memoriam: Notable people who died in 2023

explore

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Sweden knocks USA out of World Cup in penalty kicks

2:22UnitedStates'MeganRapinoe,right,reactswithherteammatesfollowingtheirlosstoSwedenintheirWomen'sWo

Continuity nursing helped my family in our darkest PICU moments

EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

MEXICOCITY--Mexico’simmigrationagencysaidlateFridayitfound491migrantsbeingheldatacompoundbythesideof